Emibetuzumab (Anti-HGFR / c-Met) c-Met null | Read Reviews & Product Use Citations

Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.

Purity & Quality Control

≥99

Choose Selective c-Met Inhibitors

Name	Citation	c-Met	Others
Foretinib	93	++++	KDR,Tie-2,VEGFR3/FLT4
PHA-665752	91	++	RON,Flk1
SU11274	63	+
SGX-523	133	+++
BMS-777607	56	+++	Axl,RON,Tyro3
Tivantinib	47	+
JNJ-38877605	52	+++
PF-04217903	22	++
MGCD-265 analog	12	++++	RON,VEGFR2,VEGFR1
BMS-754807	50	++	Insulin Receptor,IGF-1R,TrkB
BMS-794833	1	+++	VEGFR2
AMG-208	0	++
MK-2461	4	++++	c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100)
Golvatinib (E7050)	8	+	VEGFR2
AMG-458	0	++++
Tepotinib	18	+++
NVP-BVU972	1	+
Savolitinib (AZD6094)	15	++	p-Met
S49076	1	++++	Mer,Axl,FGFR3
Merestinib (LY2801653)	9	+++
AMG 337	2	++++
NPS-1034	3	+	Axl

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.

References
[1] Liu L, et al. Clin Cancer Res. 2014 Dec 1;20(23):6059-70.

References

[1] Liu L, et al. Clin Cancer Res. 2014 Dec 1;20(23):6059-70.

Product Details

CAS No.	1365287-97-3
Molecular Weight	144.56
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field